Nanomaterials and Neurological Disorders Management

Neurodegenerative diseases (NDs) is the most common illnesses that affect majorly our healthcare systems including dementia, Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. As no specific treatments are available to pass the blood–brain barrier (BBB) and significantly reach the brain for the pharmacological impact, these ailments are regarded as incurable diseases. It is still difficult to create diagnostic and therapeutic tools for the surveillance and treatment of these disorders. The recent use of specialized nanomaterials (nanocarriers and nanoparticles) has improved diagnosis and therapies for neurodegenerative illnesses. The immense potential of nanopharmaceuticals as carriers for the spatial and temporal distribution of bioactive and diagnostics in drug delivery has recently come to light. Numerous pharmaceutical nanotechnology-based systems, also known as nanopharmaceuticals, have revolutionized both drug delivery and the entire medical system. These include polymeric nanoparticles, magnetic nanoparticles, liposomes, carbon nanotubes, quantum dots, dendrimers, metallic nanoparticles, polymeric nanoparticles, etc. These nanoparticles are employed recurrently for imaging studies and the treatment of neurological illnesses because of their distinctive properties, which include sensitivity, selectivity, and the capacity to cross the BBB when used in nano-sized particles.